Cingulate Inc., a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Kansas City, Kansas, focuses on developing product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD). The company incurred an income tax expense of -$263.00 indicating its tax obligations, while the gross profit stands at -$653,090.00 highlighting the company's profitability from core operations. Its income before tax ratio is $0.00 reflecting the pre-tax margin and providing insights into its financial performance. Furthermore, the weighted average number of diluted shares outstanding is $3,811,993.00 reflecting potential dilution effects that could impact earnings per share. Cingulate also earned an interest income of $0.00 showcasing its effective financial investments. The primary product candidates include CTx-1301 (dexmethylphenidate), which is currently in a phase 3 clinical trial, and CTx-1302 (dextroamphetamine) aimed at treating ADHD. Additionally, the company is developing CTx-2103 for anxiety disorders, positioning itself as an innovator in mental health therapies. In the context of market dynamics, the stock is affordable at $3.54 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of $159,735.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $22,467,004.00 Cingulate Inc. is classified as a small-cap player, signaling its growth potential within the biopharmaceutical landscape. As a key player in the Biotechnology industry, Cingulate contributes significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth forward. The company's focus on ADHD and anxiety disorder treatments may position it favorably for future developments and opportunities within the healthcare market.